5 Stocks Racking Up Monster Gains

3. Oruka Therapeutics Inc. (NASDAQ:ORKA)

Oruka Therapeutics soared to a new record high on Monday, as investors positioned portfolios following positive results from the clinical study of its psoriasis treatment candidate, ORKA-001.

In an updated report, Oruka Therapeutics Inc. (NASDAQ:ORKA) said that 40 of the 63 enrolled patients treated with ORKA-001 achieved the primary endpoint of PASI 100 at Week 16, representing a complete skin clearance.

Based on a cross-trial comparison, ORKA-001 demonstrated numerically higher rates of skin clearance than all other IL-23p19 inhibitors.

Additionally, ORKA-001 recorded a safety profile and recorded no serious treatment-emergent adverse effects.

Following the news, shares of Oruka Therapeutics Inc. (NASDAQ:ORKA) climbed to their highest price of $91 in intra-day trading on Monday before paring gains to finish the session just up by 10.66 percent at $76.39 apiece.

“These data reached the top end of what we could have expected from ORKA-001 across efficacy, tolerability, and potential for long-lasting response,” Oruka Therapeutics Inc. (NASDAQ:ORKA) Chief Medical Officer Joana Goncalves said.

“We’re thrilled with the profile that is emerging for this program and are excited to see how the data matures with longer-term follow-up,” she added.

Longer-term data from the study, covering 28 weeks of treatment, is set to be provided in the second half of the year.